Authorized purpose: vascuCAP analyzes contrast multidetector CT of arterial vessels to support atherosclerosis stratification with color maps, three-dimensional views, multiplanar reformats, and measurements for physician review.
Clinical role
Medical-image processing, measurement, quantification, visualization, and reporting support.
Images and patients
CT/CTA · Heart/Cardiovascular
Key limitation
Keep in mind: The measurements provided by vascuCAP are not intended to provide a diagnosis or clinical recommendations. vascuCAP is intended as a tool to complement standard of care. Stenosis by diameter may be overestimated when the lumen becomes appreciably smaller than the finite voxel size; quantitative calculations should be disregarded when the lumen is not readily visualized and judged qualitatively.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: vascuCAP analyzes contrast multidetector CT of arterial vessels to support atherosclerosis stratification with color maps, three-dimensional views, multiplanar reformats, and measurements for physician review.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Heart/Cardiovascular Input: Multi-dimensional digital images acquired with contrast from CT imaging devices, including images obtained using a multidetector CT.
Who uses it?Intended users: Trained physicians.
What does the software produce?Output: Measurement and visualization using color-coded maps of arterial vessels, including a highlighted vessel in 3D, rotatable curved MPR vessel views, vessel cross sections, lumen boundaries, stenosis measurements, maximum and minimum lumen diameters, Hounsfield unit or signal intensity statistics, and vessel length along the centerline.
What is its most important limitation?Key limitation: The measurements provided by vascuCAP are not intended to provide a diagnosis or clinical recommendations. vascuCAP is intended as a tool to complement standard of care. Stenosis by diameter may be overestimated when the lumen becomes appreciably smaller than the finite voxel size; quantitative calculations should be disregarded when the lumen is not readily visualized and judged qualitatively.
Clinical takeaway. Clinical role: vascuCAP analyzes contrast multidetector CT of arterial vessels to support atherosclerosis stratification with color maps, three-dimensional views, multiplanar reformats, and measurements for physician review.
Evidence takeaway. Evidence from the reviewed source record: K183012 reports software, measurement, visualization, and clinical testing for arterial CT analysis. Measurements are not intended to establish a diagnosis or clinical recommendation and complement standard of care; the public FDA summary does not provide a reliable single sensitivity or specificity value.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
vascuCAP analyzes contrast multidetector CT of arterial vessels to support atherosclerosis stratification with color maps, three-dimensional views, multiplanar reformats, and measurements for physician review.
Exact FDA submission
Checked 2026-09-19
Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.
Measurement and visualization using color-coded maps of arterial vessels, including a highlighted vessel in 3D, rotatable curved MPR vessel views, vessel cross sections, lumen boundaries, stenosis measurements, maximum and minimum lumen diameters, Hounsfield unit or signal intensity statistics, and vessel length along the centerline.
Exact FDA submission
Checked 2026-09-19
The exact indication lists the supported vessel visualization and measurement functions; unsupported segmentation and report claims are removed.
The measurements provided by vascuCAP are not intended to provide a diagnosis or clinical recommendations. vascuCAP is intended as a tool to complement standard of care. Stenosis by diameter may be overestimated when the lumen becomes appreciably smaller than the finite voxel size; quantitative calculations should be disregarded when the lumen is not readily visualized and judged qualitatively.
Exact FDA submission
Checked 2026-09-19
The exact indications and performance discussion state the diagnostic boundary, standard-of-care role, and stenosis-by-diameter caveat.
K183012 reports software, measurement, visualization, and clinical testing for arterial CT analysis. Measurements are not intended to establish a diagnosis or clinical recommendation and complement standard of care; the public FDA summary does not provide a reliable single sensitivity or specificity value.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
K183012 reports software, measurement, visualization, and clinical testing for arterial CT analysis. Measurements are not intended to establish a diagnosis or clinical recommendation and complement standard of care; the public FDA summary does not provide a reliable single sensitivity or specificity value.
Sensitivity is not the primary endpoint for this system, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-03
Specificity is not the primary endpoint for this system, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K183012 FDA performance package for vascuCAP
DesignManufacturer analytical, software, measurement, visualization, and clinical validation
PopulationContrast multidetector CT examinations of arterial vessels for atherosclerosis stratification
Scopeexact submission
Tested versionvascuCAP
IndependenceSponsor or vendor study
K183012
Manufacturer evidence submitted for FDA clearance or approval; local clinical, technical, and workflow acceptance remains necessary.
5 unlinked candidate evidence records are retained for source review and excluded from this evidence display.
Safety and lifecycle
Postmarket record
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K183012 by exact submission identifier. This does not exclude product-family, later, or adverse-event information.
Public source
Exact FDA submission
Checked 2026-09-03
Exact-identifier review does not prove absence of all product-family safety signals.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Multi-dimensional digital images acquired with contrast from CT imaging devices, including images obtained using a multidetector CT.
Scope: Exact FDA submission. The exact indication and device description define the contrast-enhanced CT image input.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: DICOM import and output to PACS, reporting, or downstream systems; validate identifiers, series selection, measurements, units, geometry, routing, and round trips.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: Measurement and visualization using color-coded maps of arterial vessels, including a highlighted vessel in 3D, rotatable curved MPR vessel views, vessel cross sections, lumen boundaries, stenosis measurements, maximum and minimum lumen diameters, Hounsfield unit or signal intensity statistics, and vessel length along the centerline.
Scope: Exact FDA submission. The exact indication lists the supported vessel visualization and measurement functions; unsupported segmentation and report claims are removed.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Measurement and visualization using color-coded maps of arterial vessels, including a highlighted vessel in 3D, rotatable curved MPR vessel views, vessel cross sections, lumen boundaries, stenosis measurements, maximum and minimum lumen diameters, Hounsfield unit or signal intensity statistics, and vessel length along the centerline.
Scope: Exact FDA submission. The exact indication lists the supported vessel visualization and measurement functions; unsupported segmentation and report claims are removed.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
DICOM import and output to PACS, reporting, or downstream systems; validate identifiers, series selection, measurements, units, geometry, routing, and round trips.
Only qualified imaging professionals and physicians trained for the represented anatomy and workflow should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Measurements and maps are adjunctive and are not intended to make a diagnosis or clinical recommendation. Verify contrast timing, arterial coverage, reconstruction, manual edits, and the exact validated vessel set locally.
DICOM import and output to PACS, reporting, or downstream systems; validate identifiers, series selection, measurements, units, geometry, routing, and round trips.
exact submission · checked 2026-09-03
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally. The capability is derived from the exact FDA workflow and still requires local acceptance testing.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Measurements and maps are adjunctive and are not intended to make a diagnosis or clinical recommendation. Verify contrast timing, arterial coverage, reconstruction, manual edits, and the exact validated vessel set locally.
exact submission · checked 2026-09-03
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-03
No exact-product price was found in the reviewed public material; vendor productivity claims are scenario inputs, not guaranteed local savings.
Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Measurements and maps are adjunctive and are not intended to make a diagnosis or clinical recommendation. Verify contrast timing, arterial coverage, reconstruction, manual edits, and the exact validated vessel set locally.
exact submission · checked 2026-09-03
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. The capability is derived from the exact FDA workflow and still requires local acceptance testing.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
The exact indication states that images are acquired with contrast from CT imaging devices and post-processed from multidetector CT. Controlled directory display reconciled from exact FDA wording: Contrast-enhanced multidetector CT. -> CT/CTA.
The exact indication identifies arterial vessels as the represented anatomy and does not establish the dossier's heart/cardiovascular label. Controlled directory display reconciled from exact FDA wording: Arterial vessels. -> Heart/Cardiovascular.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
28Fields reviewed
13Source classes checked
5Screened PubMed leads
3Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 5 PubMed and 3 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 5 PubMed and 3 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission
No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-03 - Exact FDA submission
Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.
Authorized purpose: cvi42 Coronary Plaque supports qualified professionals with viewing, post-processing, and qualitative and quantitative evaluation of adult cardiac CT DICOM images to assess the presence and extent of coronary plaques and stenoses in CCTA for CAD or suspected CAD.
Authorized purpose: Adjunctive opportunistic detection and quantification of aortic valve calcification during routine clinical-care chest CT review; a physician reviews the informational ROI and estimated calcium burden and decides any further action.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.